Rapidly Increasing Despite Worldwide Pandemic
From the Second Quarter 2021 TMIST Study Updates Newsletter
Posted July 16, 2021
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) has now enrolled more than 50,000 women and secured 111 study sites in the United States and abroad. One of the fastest growing National Cancer Institute (NCI)–sponsored trials, TMIST participation has doubled since the start of the COVID-19 pandemic.
TMIST is the first randomized, controlled trial to identify women in which digital breast tomosynthesis (DBT) may outperform two-dimensional (2D) digital mammography in reducing advanced breast cancer development. The study will also create the world’s largest curated dataset of breast cancer screening clinical data, images and biospecimens to help researchers tailor future screening to a woman’s individual risk.
“Since the CDC-recommended non-urgent care shutdown ended in July 2020, TMIST has gained more patients than all other NIH trials. Yet, more sites and women are needed. Facilities with tomosynthesis and digital mammography should visit acr.org/TMIST and contact TMIST staff to take part,” said TMIST Study Chair Etta Pisano, MD, FACR.
TMIST is recruiting one of the most racially diverse populations of any NCI trial. Currently, 19% of U.S. women in the study are Black. The average Black cohort in U.S. clinical trials is 8%. To date, nearly 25% of TMIST participants are Hispanic.
Only 44% of accredited mammography scanners are DBT units, and 23% of U.S. imaging facilities do not have DBT scanners. Many of these sites may be in underserved areas. A Journal of the American College of Radiology (JACR®) study showed that Black women are far less likely to be screened with DBT than white or Asian women.
“TMIST funding provides payment for mammography screening for those participants who qualify for charity care at their participating site. The trial may be the only way for many women in underserved and rural areas to access any routine screening – much less DBT,” said Peter O’Dwyer, MD, co-chair of the ECOG-ACRIN Cancer Research Group, which is leading TMIST.
The NCI will continue to fund TMIST and work with the ECOG-ACRIN Cancer Research Group to modify TMIST to more quickly complete accrual and answer the primary study question. Site benefits, outlined in this card and video, attract non-academic, community-based women’s health services, large health systems and freestanding radiology sites.
“TMIST payment for each patient enrolled, each screening exam performed, coverage for women who qualify for charity care, and the ability for institutions to apply for a funding advance to help hire a TMIST-dedicated research coordinator make TMIST an ideal trial to take part in,” said Mitchell Schnall, MD, co-chair of the ECOG-ACRIN Cancer Research Group.
Medical imaging providers can visit acr.org/TMIST to find out how and why to take part in one of the world’s largest randomized, controlled breast cancer screening trials.
Email gro.rcanull@TSIMT with any questions regarding TMIST.
Editor’s Note to Participating Sites: Through the quarterly newsletter, the TMIST team brings you strategies and tactics that you might consider implementing at your own institution. We strongly encourage all TMIST site physicians and staff to consider submitting your own experiences for this regular series of helpful articles. If interested, please send an email to the TMIST staff.
TMIST is publicly funded by the National Cancer Institute (NCI), part of the National Institutes of Health, through the NCI Community Oncology Research Program.